AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02651805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation-Exsufflation
Description: Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
Study NCT02651805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Insufflation-Exsufflation
Description: Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
Study NCT02651805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
Study NCT01472757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR506
Description: VR506 inhalation powder delivered via a new dry powder inhaler
Study NCT01472757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered via a new dry powder inhaler
Study NCT03757637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NLSCP
Description: Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in this groups will further receive either NLSCP (Exp-1). Patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). This group will receive a face-to-face education or counseling by trained research nurse.
Study NCT03757637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICT supported HAP
Description: Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in the groups will further receive ICT supported HAP (Exp-2) intervention. For this groups, patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). The group will receive the interactive mobile phone App.
Study NCT03195023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Study NCT03195023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
Study NCT03444051 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-FNB with 20-gauge Procore® needle
Description: Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle
Study NCT03444051 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-FNB with 22-gauge Acquire® needle
Description: Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
Study NCT01902758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan and theophylline
Study NCT01902758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for comparison group
Study NCT02308813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Braking and functionality
Study NCT00948506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% topical cidofovir
Description: 1% topical cidofovir
Study NCT00948506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3% topical cidofovir
Description: 3% topical cidofovir
Study NCT02515656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLYGYNAX®
Study NCT00948506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical placebo
Study NCT02515656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GYNODAKTARIN®
Study NCT02515656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03982875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alfred SmartBag
Description: The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
Study NCT04192058 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Description: For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
Study NCT04192058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) it is a therapeutic method that modulates membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively. The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min.
Study NCT01458717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation
Description: * Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* 4 weeks rest, re-evaluation for resectability~* operation~* start maintenance chemotherapy within 4\~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle
Study NCT01458717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upfront surgery
Description: * Operation at time of diagnosis~* Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* start maintenance chemotherapy within 4\~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle
Study NCT02679833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Toothpaste not containing the vitamin.
Study NCT02679833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cyanocobalamin
Description: Toothpaste containing100 µg cyanocobalamin/g.
Study NCT03153267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 MG Oral Tablet bid, 7 days
Description: Patients will receive doxycycline for 7 days.
Study NCT03153267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 MG Oral Tablet bid, 14 days
Description: Patients will receive doxycycline for 14 days.
Study NCT03153267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Controls without a history of lyme disease.
Description: No intervention.
Study NCT00659698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)
Description: artificial pancreas
Study NCT06133946 — intervention group
Intervention type: GENETIC
Intervention: Genetic screening test (Deafness gene variant detection array kit)
Description: Infant participants were screened for fifteen variants in four genes (i.e., GJB2, SLC26A4, MT-RNR1 and GJB3).
Study NCT01485445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (200mcg unit strength)
Description: inhalation powder
Study NCT01485445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol (200/25mcg unit strength)
Description: inhalation powder
Study NCT02957045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough pressure measurement
Study NCT02957045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pcough
Study NCT00951834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-Gallate
Description: Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~* Months 1-3: 200 mg EGCG/die (200-0-0 mg)~* Months 4-6: 400 mg EGCG/die (200-0-200 mg)~* Months 7-9: 600 mg EGCG/die (400-0-200 mg)~* Months 10-18: 800 mg EGCG/die (400-0-400 mg)
Study NCT00951834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04605432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-FFI
Description: Patients with risk factor : on the day before the colonoscopy at 20:00- 21:00 hours, 60gPEG-4000 was mixed with 1L water; 4-6 h before colonoscopy, 120gPEG-4000 was mixed with 2L water.~Patient without risk factor: 4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by experienced researcher.
Study NCT04605432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-nonFFI
Description: All patients on the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by ward nurse.
Study NCT02329223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
Study NCT02329223 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Study NCT04854278 — intervention group
Intervention type: OTHER
Intervention: Massive Open Online Course (MOOC)
Description: Combination of knowledge training with video scenarios and game-based learning provided to endovascular team members: surgeons, nurses and anesthetists
Study NCT01779167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 \& 27)
Study NCT01779167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 \& 28). Lenalidomide will be initiated at a starting dose of 5 mg.
Study NCT01779167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
Study NCT03059706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RegenoGel-OSP™
Description: intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery
Study NCT03059706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intra-articular injection of saline after arthroscopic surgery
Study NCT01730651 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: IMRT boost of gross LNs~1. Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~2. Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)
Study NCT04101032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eBEfree
Description: Contextual interventions based on promoting acceptance,mindfulness and self-compassion abilities
Study NCT02307084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of the long saphenous vein
Description: Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
Study NCT03801824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutrition Therapy
Description: Subjects will be advised on standard diet appropriate for the management of Gestational Diabetes Mellitus (GDM) designed to be high in fiber and have moderate to high dietary glycemic index
Study NCT02306213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch 6% 130/0.4
Description: Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
Study NCT02306213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard volume therapy
Study NCT02306213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard volume therapy
Study NCT02782598 — intervention group
Intervention type: DEVICE
Intervention: CRT+NAVH
Description: Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
Study NCT02217241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handoff Workshop
Study NCT03067610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
Study NCT03067610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
Study NCT02591914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fovista™
Description: Anti-PDGF-B pegylated aptamer
Study NCT02591914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis®
Description: Anti-VEGF
Study NCT02591914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin®
Description: Anti-VEGF
Study NCT02591914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea®
Description: Anti-VEGF
Study NCT01319864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor Dose Escalation
Description: Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy.
Study NCT04208542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: Ultrasound guided Erector spinae block (ESP) will perform.
Study NCT00420563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYCLOPHOSPHAMIDE
Description: 50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
Study NCT00420563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEGESTROL
Description: 320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
Study NCT02004132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axiron
Description: Solution administered topically using pump and applicator
Study NCT01307917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavonoids
Description: for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
Study NCT01307917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavonoids
Description: for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
Study NCT02759887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biospecimen collection
Description: Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
Study NCT02759887 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cognitive assessments
Description: Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
Study NCT02759887 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: caregiver questionnaire
Study NCT02759887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Florbetapir F18 imaging
Description: Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
Study NCT02759887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: Magnetic resonance imaging of the head and brain.
Study NCT02759887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fludeoxyglucose F18 (FDG)
Description: Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
Study NCT03801824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index
Description: Subjects will be advised to eat low glycemic index foods
Study NCT00088959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00088959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally
Study NCT00088959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02180802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Study NCT02180802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing with parental involvement
Study NCT02180802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Study NCT03193658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolumbar Interfascial Plane (TLIP) block
Description: A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.~The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally.